Compare Adaptive Biotechnologies Corp (ADPT) vs Affirm Holdings Inc (AFRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Affirm Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Affirm Holdings Inc trades at $77.12 (market cap $25.30B). The key difference: Affirm Holdings Inc is far larger — about 6.2× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Affirm Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | AFRM | |
|---|---|---|
Market Cap | $4.05B | $25.30B |
Sector | Health | Financials |
52-Week High | $25.45 | $92.18 |
52-Week Low | $12.30 | $42.53 |
Enterprise Value | $4.12B | $31.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
AFRM trades at $75.25, down 1.74% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $3.22B in 2025, turning profitable with net income of $52.19M, and has beaten EPS estimates in recent quarters. Positive sentiment is driven by analyst optimism and expanding merchant partnerships.
Outlook remains favorable with a consensus price target of $96.00, indicating 28% upside. Risks include high valuation multiples (P/E 68.41) and sensitivity to interest rate changes. Continued execution on growth and profitability will be key for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →
